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Abstract
The most difficult clinical questions in stroke rehabilitation are ‘‘What is this patient’s potential for recovery?’’ and
‘‘What is the best rehabilitation strategy for this person, given her/his clinical profile?’’ Without answers to these
questions, clinicians struggle to make decisions regarding the content and focus of therapy, and researchers design
studies that inadvertently mix participants who have a high likelihood of responding with those who do not.
Developing and implementing biomarkers that distinguish patient subgroups will help address these issues and unravel
the factors important to the recovery process. The goal of the present paper is to provide a consensus statement
regarding the current state of the evidence for stroke recovery biomarkers. Biomarkers of motor, somatosensory,
cognitive and language domains across the recovery timeline post-stroke are considered; with focus on brain structure
and function, and exclusion of blood markers and genetics. We provide evidence for biomarkers that are considered
ready to be included in clinical trials, as well as others that are promising but not ready and so represent a developmental
priority. We conclude with an example that illustrates the utility of biomarkers in recovery and rehabilitation research,
demonstrating how the inclusion of a biomarker may enhance future clinical trials. In this way, we propose a way forward
for when and where we can include biomarkers to advance the efficacy of the practice of, and research into, rehabili-
tation and recovery after stroke.
Keywords
Biomarker, motor, somatosensory, cognition, language, stratification, function, clinical trial, neuroimaging, human
Received: 9 February 2017; accepted: 15 May 2017
1Department of Physical Therapy & the Djavad Mowafaghian Centre for
Brain Health, University of British Columbia, Vancouver, Canada
2Department of Physical Therapy, University of British Columbia,
Vancouver, Canada; Stroke Division, The Florey Institute of
Neuroscience and Mental Health, Heidelberg, Australia
3Sobell Department of Motor Neuroscience, UCL Institute of Neurology,
Queen Square, London, UK
4Department of Medicine and Centre for Brain Research, University of
Auckland, Auckland, New Zealand
5Inserm U 1127, CNRS UMR 7225, Sorbonne Universite´s, UPMC Univ
Paris 06, UMR S 1127, Institut du Cerveau et de la Moelle e´pinie`re, ICM,
Paris, France
6AP-HP, Urgences Ce´re´bro-Vasculaires, Hoˆpital Pitie´-Salpeˆtrie`re, Paris,
France
7Division of Rehabilitation & Ageing, University of Nottingham,
Nottingham, UK
8Department of Neurology, Washington University in Saint Louis, St
Louis, MO, USA
9Department of Brain Repair and Rehabilitation, Institute of Neurology &
Institute of Cognitive Neuroscience, University College London, Queens
Square, London, UK
10School of Health & Rehabilitation Sciences, University of Queensland,
Brisbane, Australia; and University of Queensland Centre for Clinical
Research, Brisbane, Australia
11School of Allied Health, College of Science, Health and Engineering, La
Trobe, University, Bundoora, Australia; and Neurorehabilitation and
Recovery, Stroke Division, The Florey Institute of Neuroscience and
Mental Health, Heidelberg, Australia
12Human Cortical Physiology and Neurorehabilitation Section, NINDS,
NIH, Bethesda, MD, USA
13School of Health and Rehabilitation Sciences, The Ohio State
University, Columbus, OH, USA
14Faculty of Health, University of Technology, Ultimo, Sydney, Australia
15University of California, Irvine, CA, USA; Depts. Neurology, Anatomy &
Neurobiology, and Physical Medicine & Rehabilitation, Irvine, CA, USA
Corresponding author:
Lara A Boyd, University of British Columbia, 212, 2177 Wesbrook Mall,
Vancouver, BC V6T 1Z4, Canada.
Email: lara.boyd@ubc.ca
International Journal of Stroke, 12(5)
International Journal of Stroke
2017, Vol. 12(5) 480–493
! 2017 World Stroke Organization
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1747493017714176
journals.sagepub.com/home/wso
Introduction
Stroke is a heterogeneous condition, making choice of
treatment, and prediction of outcome and treatment
response, diﬃcult. Despite this, clinical trials are often
designed with a ‘one size ﬁts all’ point of view, which
can make them vulnerable to patient heterogeneity,
reduced statistical power, and thus failure.
Biomarkers can greatly inform patient selection for
trials in general medical research, and this is equally
true for stroke recovery. A stroke recovery biomarker
(SRB) can be deﬁned as an indicator of disease state
that can be used as a measure of underlying molecular/
cellular processes that may be diﬃcult to measure dir-
ectly in humans, and could be used to understand out-
come, or predict recovery or treatment response.1
In practical terms, biomarkers should improve our
ability to predict long-term outcomes after stroke
across multiple domains. This is beneﬁcial for: (a)
patients, caregivers and clinicians; (b) planning subse-
quent clinical pathways and goal setting; and (c) iden-
tifying whom and when to target, and in some instances
at which dose, with interventions for promoting stroke
recovery.2 This last point is particularly important as
methods for accurate prediction of long-term outcome
would allow clinical trials of restorative and rehabilita-
tion interventions to be stratiﬁed based on the potential
for neurobiological recovery in a way that is currently
not possible when trials are performed in the absence of
valid biomarkers. Unpredictable outcomes after stroke,
particularly in those who present with the most severe
impairment3 mean that clinical trials of rehabilitation
interventions need hundreds of patients to be appropri-
ately powered. Use of biomarkers would allow incorp-
oration of accurate information about the underlying
impairment, and thus the size of these intervention
trials could be considerably reduced,4 with obvious
beneﬁts. These principles are no diﬀerent in the context
of stroke recovery as compared to general medical
research.5
Interventions fall into two broad mechanistic cate-
gories: (1) behavioural interventions that take
advantage of experience and learning-dependent plasti-
city (e.g. motor, sensory, cognitive, and speech and lan-
guage therapy), and (2) treatments that enhance the
potential for experience and learning-dependent plasti-
city to maximise the eﬀects of behavioural interventions
(e.g. pharmacotherapy or non-invasive brain stimula-
tion).6 To identify in whom and when to intervene,
we need biomarkers that reﬂect the underlying bio-
logical mechanisms being targeted therapeutically.
Our goal is to provide a consensus statement regard-
ing the evidence for SRBs that are helpful in outcome
prediction and therefore identifying subgroups for
stratiﬁcation to be used in trials.7 We focused on
SRBs that can investigate the structure or function of
the brain (Table 1). Four functional domains (motor,
somatosensation, cognition, and language (Table 2))
were considered according to recovery phase post
stroke (hyperacute: <24 h; acute: 1 to 7 days; early sub-
acute: 1 week to 3 months; late subacute: 3 months to 6
months; chronic:> 6 months8). For each functional
domain, we provide recommendations for biomarkers
that either are: (1) ready to guide stratiﬁcation of sub-
groups of patients for clinical trials and/or to predict
outcome, or (2) are a developmental priority (Table 3).
Finally, we provide an example of how inclusion of a
clinical trial-ready biomarker might have beneﬁtted a
recent phase III trial. As there is generally limited evi-
dence at this time for blood or genetic biomarkers, we
do not discuss these, but recommend they are a devel-
opmental priority.9–12 We also recognize that many
other functional domains exist, but focus here on the
four that have the most developed science.
A challenge across the reviewed literature was to
determine where the biomarker data explained recovery
beyond that denoted by clinical outcome measures,
such as the proportional recovery rule that has been
demonstrated using motor,3,13 visuospatial neglect14
and language15 outcomes. Given the recency of these
models, we were unable to address this in this paper
and urge people to consider this in their future trial
design. Further, to fully understand the predictive
Table 1. Summary of possible brain biomarkers to measure brain structure or function
Measures of structure/injury: Measures of function:
 Computed tomography (CT)
 Diffusion tensor imaging (DTI)
 Diffusion weighted imaging (DWI)
 Fluid Attenuation Inversion Recovery (FLAIR)
 Gradient echo and spin echo (GRASE)
 T1-weighted MRI
 T2-weighted MRI
 Proton density-weighted MRI
 Electroencephalograpy (EEG)
 Functional magnetic resonance imaging (fMRI)
 Magnetoencephalography (MEG)
 Magnetic resonance spectroscopy (MRS)
 Near Infrared Spectroscopy Imaging (NIRSI)
 Positron emission tomography (PET)
 Resting state magnetic resonance imaging (rsMRI)
 Sensory electroencephalography (sEEG)
 Transcranial magnetic stimulation (TMS)
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capacity of biomarkers, we need to move beyond cross-
sectional studies, which constitute the bulk of the bio-
marker literature at present, and conduct mechanistic
studies that go beyond simple correlations, as well as
conduct longitudinal studies that provide data useful
for predicting outcome or treatment response.
Motor
Neuroimaging biomarkers include quantitative charac-
terisation of the stroke lesion itself, as well as the struc-
ture and function of non-lesioned brain areas. There is
little consensus regarding the usefulness of characteriz-
ing the ischemic penumbra at the hyper-acute stage in
relation to predicting motor outcomes. Recent data
suggest that the site of ischemic penumbra, rather
than volume, could predict outcome or treatment
response (i.e. to thrombolysis) and aﬀect motor recov-
ery.16 Acute infarct volume correlates with motor out-
come (National Institute of Health Stroke Severity
(NIHSS)), but this relationship is attenuated with
increasing leukoaraiosis severity.17,18 The extent of
existing white matter disease (i.e. leukoaraiosis) has
been associated with acute lesion size, degree of lesion
expansion and stroke severity indicated by initial
NIHSS score.19 These ﬁndings underscore the point
that biomarker performance varies across diﬀerent
stroke subgroups.
Measures of corticospinal tract (CST) white matter
integrity in the acute stage may predict motor outcome.
Early measurement of CST ﬁber number via diﬀusion
tensor imaging (DTI), a reﬂection of white matter
integrity, predicts motor outcome (Fugl–Meyer score)
at 12 months, especially for patients with initially more
severe impairment.20 Other data,21 though not all,22
also suggest that fractional anisotropy (FA) of the ipsi-
lesional and contralesional CST at the acute stage is
higher in individuals who achieve better motor recovery
after stroke. Data also support the potential utility of
the asymmetry between the ipsilesional and contrale-
sional CST FA to predict treatment gains in the chronic
stage.23
Measures of the extent of CST injury in the acute
stage, such as via CST lesion load,24 also have predict-
ive value for poor motor outcome. A model including
this biomarker improved prediction of Fugl–Meyer
motor score at three months post-stroke that was
beyond what could be determined by baseline behav-
ioral assessment, age or infarct volume. Several studies
have found that in the chronic stage, the extent of CST
injury also helps predict treatment gains.25–27
Other regions distant from the lesion inﬂuence
motor recovery. While measures related to distant
regions require further development to reach the
stage of valid biomarker, several useful observations
have been published in the chronic stage, including
those related to contralesional CST,28 corpus callo-
sum,29 precentral gyral,30 and superior longitudinal fas-
ciculi.31,32 Multivariate machine learning methods have
recently been applied to neuroimaging data with the
aim of providing individual predictions based on
an approach that integrates features extracted from
brain voxels from multiple brain areas, rather than
one area.33 In patients presenting with severe upper
limb impairment, classiﬁcation of a subsequent
good or poor recovery was more accurate using lesion
information from a range of cortical and subcortical
motor-related regions compared to just using CST
(87% compared to 73% accuracy respectively).34 Such
approaches emphasize the importance of taking
account of damage in multiple brain regions, extending
beyond CST, in order to better understand variation in
motor outcome.34–36
There is broad consensus that the presence of an
upper limb motor evoked potential (MEP) in response
to transcranial magnetic stimulation (TMS) at the
hyperacute and acute stages strongly predicts good
motor outcome37,38 and that shorter MEP latencies
Table 2. Scope of functional domains considered given exist-
ing literature
Motor refers to motor outcomes, inclusive of upper and lower
limb functions.
Sensation refers to somatosensation, touch and
proprioception.
Cognition refers to ‘executive functioning’ or ‘cognitive con-
trol’, which are umbrella terms for sub-processes of
selective attention, error monitoring, decision-making
memory and response inhibition.
Language refers to spoken language production, auditory
language comprehension, and global measures of language
function (that also include reading and writing).
Table 3. Scope for expert consensus biomarker
recommendations
Ready to be used in clinical trial means that based on the
available evidence it is recommended that the biomarker
should be included in stroke clinical trials (pilot and feasi-
bility work through to phase II/III/IV trials).
Development priority refers to biomarkers where there is some
evidence in human populations with stroke, but questions
remain or the evidence is insufficient to support the
inclusion of this biomarker in clinical trials at present.
Predictive data of outcome and/or recovery is needed to
establish its utility in clinical trials.
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and central motor conduction times are associated with
better outcome.39 The presence of a MEP has been
found to identify which patients will follow the propor-
tional recovery rule.40 Similarly, in the leg, the presence
of a MEP indicates that an individual is more likely to
be independently mobile 12 months post-stroke,41–43
yet this measure does not relate to walking recovery.13
Prediction of recovery is more challenging for patients
without an MEP40,44 and combining TMS with MRI
biomarkers may be useful in this context38 TMS
at the chronic stage helps explain the relation-
ship between corticomotor function and motor per-
formance in cross-sectional studies, and those who
have an MEP are more likely to beneﬁt from physical
interventions.23,45,46
Resting state functional connectivity (rsFC) ﬁndings
in the early and late subacute phases converge on the
conclusion that interhemispheric connectivity is of par-
ticular importance to motor control. Cross-sectional
studies have demonstrated decreased rsFC correlates
with the degree of motor impairment.47,48 The are posi-
tive associations between acute/early subacute rsFC
(ipsilesional primary motor cortex [M1] to contrale-
sional thalamus, supplementary motor area (SMA),
and medial frontal gyrus) and motor outcomes at six
months (Fugl–Meyer score).49 In late subacute patients,
the amount of CST damage combined with interhemi-
spheric M1 rsFC best predicted therapy-induced
gains.27 Fan et al.50 found that in late subacute
patients, change in interhemispheric M1-M1 rsFC pre-
dicts improvements in the Wolf Motor Function Test.
Results from a ridge regression machine-learning algo-
rithm analysis of a large sample of early subacute
stroke patients suggest that rsFC may explain a smaller
amount of the behavioral variance observed than the
amount of structural damage to the CST.51 As rsFC
can be performed in patients with severe deﬁcits after
stroke and can interrogate all brain networks simultan-
eously, it represents a priority for development.
Quantitative indices extracted from functional MRI
(fMRI) in the early and late subacute stage, such as the
laterality index from M1, and the study of its change
over time, show that stroke is associated with a less
lateralized pattern of activation as compared to healthy
subjects, a ﬁnding that is exaggerated among patients
with poorer outcomes.52,53 One unifying conclusion
across studies is that the best motor outcomes are asso-
ciated with the greatest shift towards the normal state
of brain function.54 The laterality index has been used
as a judgment criterion of eﬃcacy in the chronic stage
in trials testing mirror therapy,55 constraint-induced
therapy56 and robotic intervention protocols,57 and
can predict treatment response.58 Other fMRI metrics
such as activation volume59,60 or percent signal
change61 within key motor network nodes can predict
response to treatment in the chronic stage. As there are
fewer long-term studies of the laterality index, and it
often shows signiﬁcant biological associations, this is an
area of priority for development.
Magnetoencephalography (MEG) or electroenceph-
alography (EEG), non-invasive measures of cortical
neuronal oscillations, are sensitive to alterations in
both GABAergic and glutamatergic signalling that are
important for plasticity and recovery after stroke.62–64
Changes in cortical excitation and inhibition represent
novel therapeutic targets, but cannot be measured dir-
ectly in humans. Stroke patients with poorer outcomes
have persistent, increased low-frequency oscillations at
the acute, and early/late subacute stages,65 suggesting
predominant inhibitory mechanisms in the peri-lesional
cortex. Acutely, lower beta-rebound in response to tact-
ile ﬁnger stimulation (which indicates increased early
post-stroke sensorimotor excitability)66and increased
somatosensory map size67 predict good recovery after
stroke. Also, in a single stroke patient, zolpidem
reversed increased peri-lesional theta (4–10Hz) and
beta oscillations leading to clinical improvement.68 In
the chronic phase, dense array EEG was able to predict
motor gains from a four-week intensive training pro-
gram.69 While MEG/EEG cannot currently be recom-
mended to guide subgroup stratiﬁcation in trials at
present, this is a developmental priority.
Combining neuroimaging and neurophysiology bio-
markers may be useful for predicting motor outcomes
and therapy response.70 Upper limb outcomes at three
months can be predicted at the early sub-acute stage by
measuring ﬁrst clinical, then TMS and ﬁnally MRI bio-
markers in a stepdown approach, as in the PREP algo-
rithm.71,72 Stoykov and Stinear73 treated chronic stroke
patients using active-passive bilateral arm training and
discovered that fractional anisotropy asymmetry
between the two CST tracts accounted for 40% vari-
ability in clinical improvement. Factoring in whether
patients were MEPþ/ improved the predictive
model. One recent study emphasized that combining
neuroimaging measures of neural injury and neural
function was key to best predicting response to a stan-
dardized robotic therapy in the chronic stage.27
In summary, neuroimaging and neurophysiology
CST biomarkers can predict motor outcome and
response to therapy after stroke, and are recommended
for use in clinical trials, e.g. for stratifying patients. The
evidences for rsFC, fMRI and MEG/EEG biomarkers
are promising and are developmental priority areas
(Table 4a).
Somatosensory
Currently, there are few studies of structural or func-
tional biomarkers conducted to understand outcome,
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Table 4. Expert consensus biomarker recommendations
A) Motor
Ready to be used in clinical trial.
 CST indexed by DTI or by lesion overlap in the hypera-
cute, acute, early and late subacute, and chronic
phases, which has demonstrated a moderate to strong
relationship with impairment (outcome and recovery)
 TMS measure of MEPþ or MEP- of the upper limb to
understand and track motor recovery up to the late
subacute phase and understand the effects of rehabili-
tation interventions up to the chronic phase post-stroke.
There is evidence of a strong relationship between
impairment (outcome and recovery) and MEP status. We
recommend that future studies of upper limb interventions
determine whether patients are MEPþ or MEP- for the
purposes of stratification.
Developmental priority
 Lesion location measured in the hyperacute phase.
Identifying critical areas damaged that could predict
recovery or treatment response may be important.
Combining location and volume of stroke damage using
multivariate techniques is the next logical step.
 Leukoaraiosis and covert lesions in the hyperacute, early
and late acute and chronic phases require further
validation to understand how they impact motor recovery.
 Accumulate further evidence of the usefulness of MEPþ/
in the lower limb.
 Determining the utility of the laterality index from func-
tional MRI as a predictor of efficacy in earlier stages post
stroke is a developmental priority.
 Determine the utility of measures of rsFC and task-based
activation and MEG/sEEG to predict treatment response in
the early subacute, late subacute and chronic stages
of recovery.
B) Somatosensory
Ready to be used in clinical trial
 There are no somatosensory system biomarkers ready for
clinical trials.
Developmental priority
 Understand outcome and predict somatosensory recovery
in the acute through to chronic stages using:
* Biologically reliable measures of white matter fibre
tract integrity and connectivity within and across brain
networks e.g. using diffusion-based tractography.
* Measures of rsFC, and fMRI activation.
(continued)
Table 4. Continued
C) Cognition
Ready to be used in clinical trial
 There are no biomarkers ready to be used in clinical trials.
Developmental priority
 Understand outcome and predict recovery in the acute to
chronic stages of recovery using
* Measures of white matter integrity within both lesioned
and non-lesioned areas.
* Measures of rsFC and task-based FC.
 Predict treatment response in the early subacute, late
subacute and chronic stages of recovery using measures of
rsFC and fMRI activation.
D) Language
Ready to be used in clinical trials
 Index structural damage as per PLORAS imaging protocol
in the chronic phase of recovery to understand outcome
and predict recovery. When the PLORAS database is used
with an individual’s lesion information combined with time
post-stroke and speech behaviour it provides a strong
predictor of longitudinal aphasia recovery.
Developmental priority
 Index structural damage to and integrity of the arcuate
fasciculus with diffusion weighted imaging in the late sub-
acute and chronic phases of recovery to understand and
predict outcome.
 Predict recovery using perfusion CT and MRI in the
hyperacute phase.
 Determine if structural damage predicts therapy or treat-
ment response in the subacute through to chronic phases.
 Predict recovery and treatment response in subacute to
chronic phase using measures of task-based fMRI
activation.
 Explore measures of inter and intra-network connectivity
(including rsFC) and multivariate connectome-based
symptom mapping for prediction of outcome and treat-
ment response.
CST: corticospinal tract; CT: computed tomography; DTI: diffusion
tensor imaging; FC: functional connectivity; fMRI: functional magnetic
resonance imaging; MEPþ: motor evoked potential present; MEG: mag-
netoencephalography; MEP: motor evoked potential absent; MRI: mag-
netic resonance imaging; PLORAS: predicting language recovery and
outcome after stroke; rsFC: resting state functional connectivity; sEEG:
sensory electroencephalography.
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predict recovery or predict treatment response in the
somatosensory functioning domain in the hyperacute
or acute phases post-stroke. Most work on structural
biomarkers involving the non-lesioned brain has
focused on understanding outcome by mapping the
structural integrity of residual pathways. Feasibility of
visualisation of sensorimotor systems by tracking ﬁbres
has been demonstrated in hyperacute, acute and early
subacute phases for somatosensory symptoms.74 There
are changes in morphology of the somatosensory cortex
of chronic stroke patients,75 with co-localized structural
(cortical thickness) and functional (brain activation,
tactile stimulation) eﬀects. Only one study noted asso-
ciations between the structure of somatosensory regions
and motor outcome in the chronic phase.76
Failure to activate the somatosensory cortex during
median nerve stimulation in the acute stage predicts
poor clinical recovery at three months.77 Using MEG,
reduction in interhemispheric asymmetries of activity at
chronic compared to acute phases was associated with a
worse clinical state.78 Studies using MEG in early and
late subacute phases show that changes in source
strength of the primary somatosensory cortices correl-
ate with the extent of recovery of sensorimotor func-
tions as determined by neurological exams (e.g.
graphesthesia test).79 Yet, MEG can be complicated
to employ, and so broader evaluation of these ﬁndings
might beneﬁt from use of less complex electrophysio-
logical methods such as EEG. In the subacute phase,
diﬀerences in brain activity measured with task-related
fMRI correlated with touch impairment in patients
with thalamus/internal capsule lesions compared to
those with lesions of primary (SI) or secondary (SII)
somatosensory cortex.80 Similarly, responsiveness of
SI at 1–15 days post-stroke is associated with improve-
ment of two-point discrimination three months post-
stroke.81 Resting-state FC studies of touch impairment
and recovery in the chronic phase demonstrated a cor-
relation between changes in connectivity from contrale-
sional SII and contralesional inferior parietal and
middle temporal gyrus with changes in a tactile discrim-
ination score that were absent in a control group.82
Associations are observed between somatosensory
function (using the Hand Active Sensation Test) and a
left/right FA ratio from the sensory component of the
superior thalamic radiation in the chronic stage83 and
the frontoparietal tracts in the acute84 and chronic85
phases. In addition, somatosensation function in the
chronic phase correlates with activity in the ipsilesional
and contralesional primary sensorimotor cortex86 and a
more distributed pattern of activity involving parietal
cortex.83 Improvement in touch discrimination at six
months was associated with increased rsFC between
seeds in the contralesional hemisphere and distributed
regions, including cerebellum.82 Using MEG,
involvement of ipsilesional primary hand representation
areas positively contributed to clinical recovery.87
Changes have also been reported in association
with training of touch discrimination,88 passive pro-
prioception89 and sensorimotor function,90 with a
focus on tracking outcomes and mechanisms, rather
than prediction. For example, touch discrimination
training of patients with somatosensory loss in the
chronic stage post-stroke was associated with diﬀerent
patterns of change in activation with thalamic/capsular
compared to SI/SII cortical lesion.88 This area of
research is a priority for development.
There is insuﬃcient evidence to recommend the use
of any speciﬁc biomarkers of somatosensory system
function in clinical trials; however, several candidates
are suggested. The recovery of somatosensation is often
overlooked despite well-documented observations that
impaired sensation is an impediment to optimal recov-
ery.91–93 Functional biomarkers, including task-related
activation and rsFC are a developmental priority
(Table 4b).
Cognition
Mapping executive/cognitive functions to speciﬁc brain
regions is problematic because these functions are dis-
tributed widely across broad brain networks, and their
relationships are complex. Indeed, studies that readily
identify structure–function relationships for phonology
and semantic processing, and often fail to ﬁnd an
equivalent for executive function.94 The most consistent
relationships were found in white matter. Frontal and
basal ganglia region microbleeds were associated with
executive dysfunction outcome in the chronic phase,95
and another study found that mean diﬀusivity of
normal appearing white matter (whole brain) in non-
lesioned areas correlated with outcomes for executive
function among individuals with ischaemic leukoaraio-
sis (plus a previous lacunar stroke).96,97 EEG changes
in frontal lobes paralleled behavioral gains across mul-
tiple cognitive domains in one study that used intensive
video gaming in health adults;98 the same may extend
to patients with stroke.
Though functional imaging methods may oﬀer the
best hope of generating robust biomarkers for executive
function, there is little published work. Available asso-
ciations are correlative and from cross-sectional
studies, rather than predictions of outcomes or more
complex evaluation of biological hypotheses. In the
late subacute phase, executive functioning correlates
with alpha band functional connectivity between
the left fronto-opercular cortex and the rest of the
brain.99 Yet, it is possible that the task-dependent
changes observed with functional imaging data have
less to do with new domain-speciﬁc areas being
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generated, and more to do with cognitive control net-
works improving residual performance.100 In individ-
uals with chronic post-stroke aphasia, a positive
correlation between task-dependent activity in midline
frontal cortex and language recovery was interpreted as
reﬂecting domain-general cognitive control systems,101
a ﬁnding that is consistent with training eﬀects in
healthy elderly subjects.98 Development of biomarkers
in this context would likely foster advances in thera-
peutic techniques to train executive function, a key pri-
ority that is feasible.102
The default mode network (DMN) has emerged as a
key biological substrate in the context of cognitive
functioning.103 Studies in the subacute and early
chronic phases report altered rsFC in the DMN corre-
lated with cognitive performance after stroke104–107 Re-
emergence of the anticorrelation between the DMN
and task-positive networks, such as the dorsal attention
network (DAN),108 is associated with behavioural
recovery of cognitive functions. Resting state studies
have provided robust examples of disruption of inter-
hemispheric connectivity associated with domain-speci-
ﬁc cognitive deﬁcits47,51,109,110 and recovery.111 In a
small longitudinal study of stroke patients compared
to healthy controls, He et al.111 showed a robust cor-
relation between left-right posterior intraparietal sulcus
rsFC and accuracy of detection of targets presented in
the left neglected visual ﬁeld. Multiple studies have con-
ﬁrmed this connectivity is much depressed in the acute
stage after stroke in persons with USN and returns
toward normal in association with the resolution of
symptoms, with the largest current longitudinal study
retaining 64 stroke patients at 12 months. Similar rela-
tionships have been reported for the DMN and other
networks.47,51,109,110 While correlational analyses
cannot establish causality and do not provide the pre-
dictive functions required of an eﬀective SRB, the ﬁnd-
ing that a change in rsFC correlates with behaviour
lends support to the idea that measures of network
connectivity have the potential to serve as useful bio-
markers across multiple behavioural domains, a possi-
bility that requires further studies.
In the domain of spatial cognition, multiple moder-
ately sized studies of right hemisphere injury conﬁrm
that damage to diﬀerent major long range white matter
tracts may predict chronic persistence of unilateral spa-
tial neglect. Two well-designed longitudinal studies
implicate the inferior occipitofrontal fasciculus and
uncinate fasciculus112 and decreased FA in the left
and right superior longitudinal fasciculus II, and for-
ceps major of the corpus callosum with neglect scores.
In cross-sectional studies, linear regression shows an
association of unilateral spatial neglect with damage
to the fronto-parietal segment of the arcuate fasciculus,
and that 78.9% and 81.6% of patients with neglect
had damage to the superior longitudinal fasciculus II
and superior longitudinal fasciculus III, respectively,
compared to only 15% and 30% in patients without
neglect.113 While damage to superior longitudinal fas-
ciculus III, arcuate fasciculus, frontal aslant, and fron-
tal inferior longitudinal fasciculus are increasingly
implicated in abnormal spatial cognition.114 Whether
damage to any of these white matter structures as
measured in the acute phase of stroke can serve as a
biomarker for persistence of USN in the chronic phase,
or in stratifying or selecting patients for interventions is
yet to be determined.
Based on this evidence, biomarkers of cognitive func-
tion, including executive functioning, are not ready for
immediate broad implementation in clinical trials. Thus,
further study and validation of biomarkers that explain
current state and future chante in cognitive functions are
a signiﬁcant priority area for development. Resting state
FC is a promising candidate biomarker (Table 4c), and
study of its utility as a biomarker of recovery is empha-
sized here.
Language
There are a number of studies identifying a relationship
between lesion site and aphasia,115 anatomical ﬁndings
that suggest potential metrics to evaluate as bio-
markers. In the hyperacute period, perfusion-weighted
MRI showed that word comprehension deﬁcits are
strongly correlated with blood ﬂow within Wernicke’s
area.116 A related study demonstrated that lexical pro-
cessing was more strongly related to the volume of
hypo-perfused tissue than the volume of lesion.117
Imaging illustrates that recovery of word comprehen-
sion from the hyperacute to acute phase (three days) is
associated with reperfusion of Wernicke’s area.118
Recovery of naming in the hyperacute period is pre-
dicted by reperfusion of left posterior middle temporal/
fusiform gyrus, Broca’s area, and/or Wernicke’s
area.119–121 There are no established predictors of long-
term (>3 days) recovery from biomarkers assessed in the
hyperacute period (<24h); thus, this is a developmental
priority.
Impaired repetition in the acute phase was asso-
ciated with structural damage to the arcuate fasciculus
and Broca’s area as well as tissue dysfunction (hypo-
perfusion and frank damage) in the inferior portion of
the left supramarginal gyrus and temporal-parietal
junction.122 Kummerer et al.,123also observed that
impaired repetition at this phase was associated with
posterior temporal-parietal lesions and damage to the
dorsal superior longitudinal and arcuate fasciculus,
while comprehension deﬁcits were associated with ven-
tral extreme capsule ﬁbre damage. Measures of func-
tional connectivity may also be useful in this phase, as a
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recent study of acute lacunar stroke patients observed
that increased resting state FC between the left and
right superior temporal gyri was correlated with
poorer language function.124
In the early subacute phase, there are relationships
between lesion location and aphasia symptoms
that suggest potential biomarkers. Kreisler et al.125cor-
rectly classiﬁed 67% to 94% of patients based on
analysis of lesion location and symptoms. Forkel
et al.,126demonstrated prediction of recovery at six
months was improved by adding volume of the left
long segment of the arcuate fasciculus to a regression
model including age, sex, and lesion size; including
volume of the right long segment of the arcuate fascic-
ulus further improved recovery prediction. Recent
work by Geranmayeh et al.,127showed that propos-
itional language production is predicted by
interactions between brain networks (DMN, fronto-
temporo-parietal, and cingulo-opercular networks)
rather than by activity within a single individual net-
work highlighting the distributed nature of language
operations. Functional MRI activity in the early sub-
acute phase shows promise as a predictor of long-term
recovery when analyzed using a multivariate machine
learning technique. Saur et al.,128employed this
method with a mask of task-induced fMRI activity in
bilateral frontal and temporal regions in combination
with behavioural language performance and age. This
approach correctly predicted good versus poor lan-
guage recovery in 86% of individuals with stroke who
had aphasia at two weeks. In the largest case-control
study of subacute stroke patients with aphasia to date,
Yang et al.124 found that in patients with lacunar
stroke, interhemispheric rsFC was increased in the
superior temporal gyrus, the inferior frontal gyrus
and the lingual gyrus. Of note is the observation that
the interhemispheric hyperconnectivity of the superior
temporal gyrus was inversely correlated with the apha-
sia quotient, indicating that greater connectivity was
associated with worse aphasia.
Voxel-based analyses in the chronic phase has estab-
lished utility in multiple brain systems and speciﬁcally
have identiﬁed structural damage associated with par-
ticular aphasic symptoms, distinguishing between
semantic and phonological processes and recognition
versus production.129–131 Arcuate fasciculus lesion
load negatively inﬂuences speech production132 and
classiﬁes severe and non-severe outcomes with 90%
accuracy for naming and 96% accuracy for speech ﬂu-
ency.133 The PLORAS (Predicting Language Outcome
and Recovery After Stroke) system134 uses a Gaussian
process model regression with a large database of
stroke patients (from one month post, therefore cover-
ing early and late subacute, and chronic phases) with
structural MRI, demographic, and language
performance to provide predictions of aphasia recovery
at the individual level. Using this approach and covari-
ate factors of time of stroke, volume, and 35 diﬀerent
brain regions, predictions of language outcome, and
within subject changes in speech production, have
been identiﬁed.135 This method has high potential to
provide measures that can serve as biomarkers to pre-
dict recovery.
Posterior middle temporal lobe damage can nega-
tively aﬀect aphasia therapy outcome in the chronic
phase.122 Meinzer et al.136observed a negative rela-
tionship between the proximity of the lesion to the
hippocampus and response to a naming treatment.
Bonilha et al.137showed that measures of neural net-
work connectivity combined with initial behavioral def-
icit severity accounted for 78% of variance in response
to anomia treatment. Several small studies identiﬁed a
relationship between therapy success and integrity of
the left arcuate fasciculus,138 right arcuate fasciculus139
and white matter in proximity to the hippocampus.136
Further, several fMRI studies have investigated treat-
ment-induced aphasia recovery, predominantly in the
chronic stage. Fridriksson122 identiﬁed a signiﬁcant
relationship between treatment-induced naming
improvements and fMRI activity in the both a poster-
ior cluster (including parietal lobe and precuneus) and
an anterior cluster (including middle frontal gyrus and
pars opercularis). Subsequent analyses140 showed that
altered activity in perilesional areas was associated
with increased naming accuracy, but measures of pre-
treatment brain activity (as opposed to changes in
activity) predicted improvement in semantic errors,
suggesting additional factors contribute to treatment
outcome. Resting state FC has also shown potential
for understanding and predicting aphasia recovery in
the subacute and chronic phases (including treatment
induced improvements); however, larger studies are
required to validate this approach.141
In summary, in the acute and early subacute stages,
the use of structural MRI provides insights into the
neural basis of language deﬁcits, but there are not suf-
ﬁcient large studies demonstrating that these methods
clearly improve prediction of recovery or treatment
response. Functional brain assessments such as via
fMRI show potential at the early subacute stage for
signiﬁcantly improving prediction of outcome;127 how-
ever, this approach needs validation. Structural MRI
and DTI may forecast recovery at the late subacute
and chronic stage, suggesting the possible use of
these techniques to stratify patients for clinical trials,
understand therapy mechanism and predict outcome.
It should be noted that: (1) there is still considerable
variability in outcome that is not accounted for by these
methods, (2) each method uses a unique and complex
analysis technique, (3) diﬀerent aphasia treatments may
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engage unique networks (Table 4d), and (4) detailed
studies examining the combined utility of anatomical
and functional brain measures for predicting language
recovery are warranted.
Conclusions
How might biomarker data be incorporated into future
stroke recovery research? As a ﬁrst point, the term
‘‘stroke’’ is inadequate, as it describes a very heteroge-
neous group of disorders that are uniﬁed by a vascular
injury, but not by size, location, or impact of injury.
Biomarkers present a way forward to subgroup or
stratify patients in order to reduce variance and
increase power, allowing for smaller sample sizes.7
Moreover, the ﬁnal behavioral phenotype after
stroke can arise from many diﬀerent biological states,
which could result in diﬀerential therapeutic responses;
functional measures are complementary to anatomical/
injury measures. Thus, a patient exploiting all possible
compensatory brain mechanisms might have little room
to improve, while a similar patient who uses no com-
pensatory mechanisms might achieve beneﬁt.142
Furthermore, inclusion of appropriate biomarkers
may improve the ability to disentangle treatment
responders from non-responders.
Clinical trials therefore need to base participant eli-
gibility on more than presence of a stroke, or behav-
ioural status. Instead, patient selection should include
appropriate biomarkers; ideally, these will be linked
with preclinical methods as well as the biological mech-
anism of the therapy or treatment under investigation.
For example, recently, a threshold was deﬁned whereby
no patient in the early and late subacute stage with
>63% injury to the CST achieved clinically important
gains associated with a robotic therapy.27 This result
highlights the ascendant role that neuroimaging meas-
ures need to play in clinical-decision making for post-
stroke rehabilitation.143
A useful example comes from the recent phase III
Everest trial,144 which relied on behavioural assess-
ments to determine participant eligibility, and ultim-
ately found that patients randomized to epidural
motor cortex stimulation did not reach the primary
eﬃcacy endpoint more often than patients in the con-
trol group. However, a post hoc analysis of patients
randomized to epidural stimulation found that the pri-
mary eﬃcacy endpoint was reached more often (67%)
by those with preserved motor evoked responses upon
cortical stimulation compared to those lacking a
response (27%).26 Thus, had conﬁrmation of physio-
logical integrity of the biological target been an eligibil-
ity criterion (as was the case in all preclinical studies
that were translated to generate this trial), the eﬀect size
would have been substantially higher and the trial
results quite diﬀerent. We believe that this example is
highly useful in illustrating the utility of biomarkers
in recovery and rehabilitation research and expect
that the inclusion of biomarkers will enhance future
clinical trials.
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